Collaboration will mix Eyenovia’s Optejet® dispensing technologies with Formosa’s APNT™ nanoparticle formulation platform for the prospective advancement of new topical therapeutics in higher-value ophthalmic indications with major unmet healthcare wants.
NEW YORK, Feb. 15, 2023 (Globe NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-business ophthalmic technologies business creating the Optejet® supply technique for use both of those in link with its individual drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as effectively as out-licensing for further indications, nowadays declared that the corporation has entered into a enhancement collaboration arrangement with Taiwan-based mostly Formosa Prescribed drugs, Inc. (6838.TWO). The settlement seeks to mix Eyenovia’s Optejet® dispensing engineering with Formosa’s special APNT™ nanoparticle formulation platform for the probable improvement of new topical ophthalmic therapeutics that employ the Optejet® dispenser.
Formosa’s proprietary and innovative APNT™ system cuts down an active pharmaceutical ingredient’s particle size with high uniformity and purity, thus allowing penetration to appropriate compartments in the eye, and finally boosting bioavailability. This reduction in ingredient size may well also increase the universe of current and foreseeable future medications that could reward from shipping and delivery using the Optejet®.
“We have assembled a big and escalating system of evidence demonstrating the quite a few advantages of Optejet®, including enhanced patient compliance and the accomplishment of therapeutic doses of treatment with considerably a lot less tension on the ocular surface than other types of administration, this kind of as conventional eye drops,” mentioned Michael Rowe, Chief Government Officer of Eyenovia. “Through this growth collaboration, we not only get obtain to Formosa’s established ophthalmic formulation expertise for even further development working with Optejet®, but also its APNT™ formulation know-how which opens up quite a few new and huge market place indications for probable growth of our personal advancement pipeline. We glimpse ahead to a extensive and mutually valuable partnership.”
“Ophthalmology represents a main target of our organization and a sizeable part of our lengthy-phrase development plan,” mentioned Erick Co, Chief Government Officer of Formosa Prescribed drugs. “With Eyenovia’s novel Optejet® dispensing platform, we believe that we can obtain a broad new range of possible employs for both equally current and recently made ophthalmic compounds. We are fired up about the possibilities and glance ahead to launching this collaboration as promptly as feasible.”
Each corporations intend to collaborate on tests formulations and participating in discussions with the Foods and Drug Administration (Food and drug administration), with the goal of executing a Growth and Commercialization Arrangement under which the companies would operate to create new medicines leveraging APNT™ formulations in the Optejet® dispenser. Further information may be found at eyenovia.com/formosa.
About Optejet® and Microdose Array Print (MAP™) Therapeutics
Eyenovia’s Optejet® microdose formulation and delivery system for ocular therapeutics employs superior-precision piezo-print technological know-how to provide ~8 μL of drug, reliable with the potential of the tear film of the eye. We estimate the volume of ophthalmic remedy administered with the Optejet® is considerably less than 20% of that delivered applying regular eyedroppers, thus reducing overdosing and publicity to drug and preservatives. Eyenovia’s patented microfluidic ejection know-how is built for fast and mild ocular surface delivery. Successful use of the Optejet® has been shown more than 85% of the time right after basic coaching in a wide variety of scientific options in comparison to 40 – 50% historically observed with conventional eyedroppers. In addition, its good electronics and cell e-well being engineering are built to keep track of and boost client compliance.
About Formosa Prescribed drugs, Inc.
Formosa Pharmaceuticals, Inc. (6838.TWO) is a clinical stage biotechnology company centered primarily in the parts of ophthalmology and oncology. The company’s proprietary nanoparticle formulation technologies (APNT™) increases the dissolution and bioavailability of lively pharmaceutical substances (APIs) for topical, oral, and inhaler administration of therapeutics. Formosa’s guide program, Application13007, a novel nanosuspension derived through APNT™ for the treatment method of swelling and agony adhering to ocular medical procedures, productively completed Period 3 trials and will be submitted to the Food and drug administration afterwards this calendar year for approval. For more data about APNT™ and Formosa Prescription drugs, take a look at www.formosapharma.com.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology organization developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is at the moment concentrated on the late-stage progress of microdosed medicines for mydriasis, presbyopia and myopia development. For a lot more details, pay a visit to Eyenovia.com.
The Eyenovia Corporate Info slide deck may be uncovered at ir.eyenovia.com/functions-and-displays.
Forward-On the lookout Statements
Other than for historic data, all the statements, expectations and assumptions contained in this presentation are forward-hunting statements. Forward-searching statements include, but are not confined to, statements that express our intentions, beliefs, expectations, approaches, predictions or any other statements relating to our upcoming things to do or other potential events or problems, together with believed sector prospects for our product candidates and platform technological know-how. These statements are centered on latest anticipations, estimates and projections about our organization centered, in section, on assumptions manufactured by administration. These statements are not guarantees of long run general performance and contain threats, uncertainties and assumptions that are tough to forecast. Thus, real outcomes and success may possibly, and in some instances are most likely to, differ materially from what is expressed or forecasted in the forward-seeking statements due to various elements reviewed from time to time in paperwork which we file with the U.S. Securities and Trade Commission.
In addition, this sort of statements could be afflicted by pitfalls and uncertainties related to, amid other matters: dangers of our medical trials, such as, but not constrained to, the prices, style, initiation and enrollment, timing, progress and outcomes of these types of trials the timing of, and our ability to post apps for, obtaining and preserving regulatory approvals for our solution candidates the likely strengths of our product or service candidates and platform technology the fee and degree of market acceptance and scientific utility of our product candidates our estimates about the prospective marketplace opportunity for our product or service candidates reliance on 3rd functions to produce and commercialize our item candidates the skill of us and our companions to well timed establish, employ and maintain production, commercialization and advertising and marketing abilities and strategies for our merchandise candidates mental home risks alterations in authorized, regulatory, legislative and geopolitical environments in the marketplaces in which we work and the impact of these improvements on our means to acquire regulatory acceptance for our items and our aggressive place.
Any ahead-wanting statements speak only as of the day on which they are built, and other than as could be expected underneath applicable securities legislation, Eyenovia does not undertake any obligation to update any forward-seeking statements.
Eyenovia Get hold of:
Chief Money Officer
Eyenovia Investor Make contact with:
LifeSci Advisors, LLC
Eyenovia Media Make contact with:
Vice President, Professional Functions